Phase 3 RCT in 480 adults with MDD and inadequate antidepressant response: adjunctive lumateperone 42 mg improved MADRS at day 43 vs placebo (LS mean difference −4.5). Discontinuation for adverse events was 12.4% vs 0.8%.
RCTn = 480
Durgam et al. Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial